RCT | Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial – Nature Medicine

News Release: Investigational drug may improve stem cell transplantation for multiple myeloma patients – Washington University in St. Louis

Commentary on Twitter

A new compound, motixafortide, can safely mobilize an optimal number of stem cells for collection and transplantation in over 90% of 80 patients with multiple myeloma with one injection, reports a phase 3 clinical trial published in @NatureMedicine. https://t.co/23bBzCyoor pic.twitter.com/d9DTs4X1cO

— Nature Portfolio (@NaturePortfolio) April 17, 2023